semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Resistance Training With Traditional Periodization Model Resistance Training With Conjugate Training Model college aged golfers with no contraindications to exercise as measured by PAR-Q+ No history of Heart condition or uncontrolled hypertension No history of chest pain at rest or with exertion No history of loss of balance or dizziness at rest or with exercise in previous 12 months No medications for chronic medical conditions No bone, joint, or soft tissue issue that could be made worse by becoming more physically active  As indicated by PAR-Q+ History of arthritis, osteoporosis, or chronic back issues Current, or recent history of, cancer Diagnosed cardiovascular disease: CAD, heart failure, diagnosed abnormality of heart rhythm Uncontrolled high blood pressure (resting blood pressure of 160/90 or greater) Diagnosed Metabolic Condition: Type 1 diabetes, Type 2 diabetes, Pre-diabetic
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Speech adult female aged 18 years old and older currently representing the nation and participating actively in rugby native speakers of Malay (national language)  did not play rugby within the last six months edentulism used a mouthguard, orthodontic appliance or removable prosthodontics appliance within the last six months known history of allergy to polymers medical problems (ASA classification 3 and above)
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Cardiovascular Diseases Heart Failure Coronary Artery Disease Mesenchymal Stem Cell Transplantation Regenerative Medicine Patients with a diagnosis of coronary disease, performed by coronary angiography, requiring conventional coronary revascularization surgery History of myocardial infarction; evidence of akinesia or regional dyskinesia more than 1 week old Ejection fraction less than 40% Age between 30 and 75 years Negative serology for HIV, hepatitis B virus (HBV), and hepatitis C virus HCV Negative pregnancy test for women of childbearing age Patients who sign the informed consent complying with all of the provisions of current regulations in Colombia  History of myocardial infarction with ST-segment elevation within 2 weeks prior to surgery History of myocardial infarction without ST-segment elevation within the previous week (the decision to these patients within the first week after suffering a non-ST elevation infarction is at the discretion of the research team) Previous history of tachycardia or ventricular fibrillation History of active neoplasia or previous chemotherapy treatment Severe or uncontrolled concomitant disease (i.e., poorly controlled chronic kidney or liver failure) Patients who, due to their place of residence, mental health or social situation, have difficulty meeting the conditions of the protocol Women who are pregnant or breast-feeding Patients or legal representatives withdrawing informed consent at any time during the study Previous history of heart transplant Patients with functional organ impairment: liver function: total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase greater than 2 times the upper reference limit; kidney function: serum creatinine > 1.5 mg/dl or creatinine clearance < 60 ml/min
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stroke Patients Patients in subacute and chronic period (3 months after stroke) Modified Ashworth scale in the hemiplegic arm with 3 or more spasticity No pain in the hemiplegic arm MMSE 20 and above Without major medical problems No previous stroke history Adequate stability to walk when healthy arm is immobilized Active 20 degrees wrist extension and 10 degrees interphalangeal and metacarpophalangeal extension (these movements should be repeated 3 times in 1 minute)  Bilateral stroke or brainstem affected Active 20-degree wrist extension and 10-degree interphalangeal and metacarpophalangeal extension Global aphasia or cognitive disorders that may affect understanding of test instructions Patients with major medical problems that may affect participation Existence of neglect
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peripheral Nervous System Diseases Nerve Compression Syndromes Carpal Tunnel Syndrome (subject diagnosed as CTS if meeting criterion 1 + at least one of 2 or 3): 1. numbness and tingling in at least two out of the first four digits; 2. symptoms exacerbated during the night or in the morning, on holding the objects or repetitive use of the hand; 3. symptoms relieved by shaking the hand or reposition of the arm. In addition to these clinical for recruitment EDx confirmation will also be needed. Only patients with bilateral EDx mild to moderate CTS will be included  polyneuropathy, symptoms of polyneuropathy, and all conditions causing polyneuropathy (e.g., diabetes); 2. multiple mononeuropathy (e.g., hereditary neuropathy with liability to pressure palsies, syndrome Lewis Sumner); 3. motor neuron disorders (e.g., monomelic amyotrophy, amyotrophic lateral sclerosis - ALS); 4. brachial plexopathy; 5. other focal neuropathies affecting upper limbs (e.g., other median neuropathies, ulnar neuropathies, thoracic outlet syndrome); or 6. previous surgery or local injections for CTS
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Alternating Hemiplegia Patients who fit the Aicardi Alternating Hemiplegia of Childhood clinical of any age. The Aicardi are six  Paroxysmal hemiplegia episodes Bilateral hemiplegia or quadriplegia episodes Other paroxysmal manifestations, such as abnormal eye movements, nystagmus, strabismus, ataxia, dystonia, choreoathetosis, tonic spells, or autonomic disturbances Evidence of permanent neurological dysfunction, which can manifest as cognitive impairment, developmental delay, and/or persistent motor deficits such as spastic diplegia/quadriplegia, hypotonia, ataxia, choreoathetosis, or dystonia Sleep relieves symptoms, although attacks may resume soon after awakening First signs of dysfunction occur prior to the age of 18 months  Patients who do not have a mutation of the ATP1A3 gene and having only some of the above Patients and / or their parents / legal guardian having provided their opposition to the study Incapacity of patient / parent or other referent adult to participate in the prospective phase of observation of different paroxysmal events of the disease and in the scoring of the Vineland II adaptive behavior scales Diagnosis of another disease, which could explain the presence of symptoms mentioned in the of Aicardi
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Cardiac Pacing Pacing Therapy Pacemaker Aged from 18 to 80 years old Subjects who are willing to provide Informed Consent Subjects who have pacing indications or indications for CRT, and will receive pacemaker or CRT therapy  Subjects who have contra-indications for pacing therapy or CRT CRT up-graded subjects Ventricular hypertrophy Subjects who have medical conditions that would limit study participation Subjects who are pregnant or have a plan for pregnancy during the study Subjects who are not willing to provide Informed Consent
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acute Ischemic Stroke Diagnosis of acute ischemic stroke according to the WHO (World Health Organization) stroke diagnostic and symptoms of stroke have existed for at least 30mins, and there is no significant improvement before treatment； The symptoms of acute ischemic stroke are expected to be less than 4.5 hours after the time of acute ischemic stroke which is defined as the last time the patient function well NIHSS score at the time of treatment: from 4 points to 24 points (including 4 points and 24 points) From the signing of informed consent form to 3 months of the last dose should be the absence of a birth plan and willing to take effective contraceptive measures Understand and follow the research process, voluntarily participate, and sign an informed consent form (informed consent is voluntarily signed by the person or legal representative)  Weight >120kg Imaging shows multiple cerebral infarction (low density > 1/3 brain hemisphere) The timing of stroke symptoms is not known mRS score before stroke≥ 2 points NIHSS score 1a (level of consciousness) ≥ 2 points during screening CT/MRI imaging examination showed signs of intracranial hemorrhage or suspected subarachnoid hemorrhage despite CT/MRI imaging findings did not show abnormalities Subjects have an acute bleeding tendency, including a platelet count of less than 100 × 109 / L, application of heparin or oral anticoagulant drugs (such as warfarin) within 24 hours before onset , and an INR > 1.6 Patients who are ready to go or have undergone endovascular treatment Patients who had severe trauma or major surgery in the last 3 months (according to the investigator's assessment) A stroke has occurred in the last 3 months; or has a history of any stroke with diabetes
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Idiopathic Inflammatory Myopathies Osteoporosis, Osteopenia All idiopathic inflammatory myopathies (IIMs) patients under follow-up in Kwong Wah Hospital are invited to participate in this study. IIMs are diagnosed by rheumatologist according to Bohan and Peter Criteria. Eligible patients will have dual-energy X-ray absorptiometry (DEXA) scan performed at baseline. 1. Adult patients of at least 18 years of age and 2. Evidence of reduced BMD in osteopenia (defined by T-score of -0.1 to -2.5) or osteoporosis range (defined by T-score of < -2.5) at baseline by dual-energy X-ray absorptiometry (DEXA) scan  Pregnant patients 2. Patients with juvenile onset of disease (<18 years of age) 3. Patients with pre-existing metabolic bone conditions 4. Patients who are already on osteoporotic treatment other than calcium and vitamin D (including bisphosphonates, denosumab, teriparatide, raloxifene or strontium) 5. Patients who are contraindicated to denosumab or zoledronic acid including severe renal impairment and hypersensitivity 6. Patients who are not able to give informed consent
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Head & Neck Cancer previously treated with radiation for head and neck malignancy Age Group: ≥30 years Patients who have no contraindications to PET/MRI No allergy to contrast agents  Pregnant females Age group: < 30 years Allergy to MR contrast agents Pacemakers/ICD/Claustrophobic patients